CRISPR Medicine News, 30 October 2020 | Your Missing Links are here - CRISPR Medicine

Your missing links are here

Top Pick




Visions and Opinion

Clinical Trials

  • Rubius Therapeutics has presented preclinical data for RTX-321, a red cell therapeutic oncology product candidate for HPV-positive cancers. The data demonstrate that RTX-321 has a dual mechanism of action by not only functioning as an antigen-presenting cell to boost HPV 16 antigen-specific T cell responses but also promoting broad immune system stimulation of both innate and adaptive immunity.


Beyond Medicine


CRISPR Medicine Jobs is Here!

We recently launched the first targeted recruitment platform for CRISPR-related jobs. Prospective employers and job seekers from all over the world can use this unique platform to find highly skilled scientists and exciting jobs within the CRISPR Medicine field!

Check out the first external job posting from the Hendel Lab in Israel right here.

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at We love hearing from readers!

Happy Reading!


p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.